FDAnews
www.fdanews.com/articles/138943-alk-phase-iii-studies-with-ragweed-allergy-immunotherapy-tablet-meet-primary-endpoints

ALK: Phase III Studies with Ragweed Allergy Immunotherapy Tablet Meet Primary Endpoints

August 3, 2011
ALK announced that two pivotal clinical Phase III studies with its investigational sublingual Ragweed Allergy Immunotherapy Tablet met the combined primary efficacy endpoint of reducing allergy symptoms and use of concomitant symptom relieving medication.
CisionWire